[1]
|
Barnes, P.J. (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology, 8, 183-192. doi:10.1038/nri2254
|
[2]
|
Cooles, F.A. and Isaacs, J.D. (2011) Pathophysiology of rheumatoid arthritis. Current Opinion in Rheumatology, 23, 233-240. doi:10.1097/BOR.0b013e32834518a3
|
[3]
|
Homey, B., Steinhoff, M., Ruzicka, T. and Leung, D.Y. (2006) Cytokines and chemokines orchestrate atopic skin inflammation. Journal of Allergy and Clinical Immunology, 118, 178-189. doi:10.1016/j.jaci.2006.03.047
|
[4]
|
Ohman, L. and Simren, M. (2010) Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nature Reviews Gastroenterology & Hepatology, 7, 163-173. doi:10.1038/nrgastro.2010.4
|
[5]
|
Fujiwara, N. and Kobayashi, K. (2005) Macrophages in inflammation. Current Drug Targets—Inflammation & Allergy, 4, 281-286. doi:10.2174/1568010054022024
|
[6]
|
Borish, L.C. and Steinke, J.W. (2003) Cytokines and chemokines. Journal of Allergy and Clinical Immunology, 111, S460-475. doi:10.1067/mai.2003.108
|
[7]
|
Rahman, I. (2002) Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: Antioxidant therapeutic targets. Current Drug Targets— Inflammation & Allergy, 1, 291-315.
doi:10.2174/1568010023344607
|
[8]
|
Fogh, K. and Kragballe, K. (2000) Eicosanoids in inflammatory skin diseases. Prostaglandins & Other Lipid Mediators, 63, 43-54.
doi:10.1016/S0090-6980(00)00096-4
|
[9]
|
Case, J.P. (2001) Old and new drugs used in rheumatoid arthritis: A historical perspective. American Journal of Therapeutics, 8, 123-143.
doi:10.1097/00045391-200103000-00007
|
[10]
|
Loung, B.T., Chong, B.S. and Lowder, D.M. (2000) Treatment options for rheumatoid arthritis: Celecoxib, leflunomide, etanercept, and infliximab. The Annals of Pharmacotherapy, 34, 743-760. doi:10.1345/aph.19344
|
[11]
|
Walsh, G.M. (2011) Novel cytokine-directed therapies for asthma. Discovery Medicine, 11, 283-291.
|
[12]
|
Afeltra, A. (2001) Treatment of rheumatoid arthritis: New therapeutic approaches with biological agents. Endocrine, Metabolic & Immune Disorders-Drug Targets, 1, 45-65.
doi:10.2174/1568008013341677
|
[13]
|
Ito, K. (2006) Update on glucocorticoid action and resistance. Journal of Allergy and Clinical Immunology, 117, 522-543. doi:10.1016/j.jaci.2006.01.032
|
[14]
|
Strehl, C., Spies, C.M. and Buttgereit, F. (2011) Pharmacodynamics of glucocorticoids. Clinical and Experimental Rheumatology, 29, S13-S18.
|
[15]
|
Schacke, H., Docke, W.D. and Asadullah, K. (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacology & Therapeutics, 96, 23-43.
doi:10.1016/S0163-7258(02)00297-8
|
[16]
|
Ezeamuzie, C.I. and Edafiogho, I.O. (2012) Enhydrazone esters for treating asthma, allergy and inflammation. US Patent No. 8,324,422 B2.
|
[17]
|
Edafiogho, I.O., Kombian, S.B., Ananthalakshmi, K.V., Salama, N.N., Eddington, N.D., Wilson, T.L., et al. (2007) Enaminones: Exploring additional therapeutic activities. Journal of Pharmaceutical Sciences, 96, 2509-2531.
doi:10.1002/jps.20967
|
[18]
|
Edafiogho, I.O., Phillips, O.A., Udo, E.E., Samuel, S. and Rethish, B. (2009) Synthesis, antibacterial and anticonvulsant evaluations of some cyclic enaminones. European Journal of Medicinal Chemistry, 44, 967-975.
doi:10.1016/j.ejmech.2008.07.005
|
[19]
|
El-Hashim, A., Yousefi, S., Edafiogho, I., Raghupathy, R., Yousif, M. and Simon, H.-U. (2010) Anti-inflammatory and immunosuppressive effects of the enaminone E121. European Journal of Pharmacology, 632, 73-78.
doi:10.1016/j.ejphar.2009.12.004
|
[20]
|
El-Hashim, A.Z., Edafiogho, I.O., Jaffal, S.M., Yousif, M.H., Ezeamuzie, C.I. and Kombian, S.B. (2011) Antitussive and bronchodilatory mechanisms of action for the enaminone E121. Life Sciences, 89, 378-387.
doi:10.1016/j.lfs.2011.07.007
|
[21]
|
Ezeamuzie, C.I. and Shihab, P.K. (2010) Interactions between theophylline and salbutamol on cytokine release in human monocytes. Journal of Pharmacology and Experimental Therapeutics, 334, 302-309.
doi:10.1124/jpet.109.163238
|
[22]
|
Cox, C.E. (2012) Persistent systemic inflammation in chronic critical illness. Respiratory Care, 57, 859-864.
doi:10.4187/respcare.01719
|
[23]
|
Franks, A.L. and Slansky, J.E. (2012) Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Research, 32, 1119-1136.
|
[24]
|
Gotzche, P. (2002) Non-steroidal anti-inflammatory drugs. Clinical Evidence, 8, 1203-1211.
|
[25]
|
Rothstein, R. (1998) Safetyt profiles of leading non-steroidal anti-inflammatory drugs. American Journal of Medicine, 105, 39S-43S.
doi:10.1016/S0002-9343(98)00280-0
|
[26]
|
Katsanou, V., Dimitriou, M. and Kontoyiannis, D.L. (2006) Post-transcriptional regulators in inflammation: Exploring new avenues in biological therapeutics. Ernst Schering Foundation Symposium Proceedings, 4, 37-57.
|
[27]
|
Stellato, C. (2004) Post-transcriptional and non-genomic effects of glucocorticoids. Proceedings of the American Thoracic Society, 1, 255-263.
doi:10.1513/pats.200402-015MS
|